@article {NAKAMURA923, author = {YUKIKO NAKAMURA and KAZUHITO MIYAZAKI and NAOTO AIKO and YUKI MISUMI and YOKO AGEMI and YURI TANIGUCHI and MARI ISHI and TSUNEO SHIMOKAWA and HIROAKI OKAMOTO and TAKEHARU YAMANAKA}, title = {Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients}, volume = {40}, number = {2}, pages = {923--928}, year = {2020}, doi = {10.21873/anticanres.14025}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: We assessed the efficacy of immune checkpoint inhibitors (ICIs) in older patients because of the limited information regarding these patients. Patients and Methods: We retrospectively analyzed 66 consecutive patients >=70 years old with advanced non-small cell lung cancer (NSCLC). A total of 31 patients received ICIs (ICIs group) and 35 patients received only cytotoxic regimens (No ICIs group). Results: Patients with squamous cell carcinoma who received ICIs had better overall survival (OS) than those who did not (9.7 versus 4.7 months, p=0.027). In multivariate analysis, treatment with ICIs [hazard ratio (HR)=0.54, 95\% confidence interval (CI)=0.30-0.98, p=0.044], good performance status (HR=0.30, 95\%CI=0.16-0.57, p=0.0003), and histology other than squamous cell carcinoma (HR=0.41, 95\%CI=0.19-0.83, p=0.014) were significantly favorable factors for OS. Conclusion: ICIs may be effective for older patients with NSCLC, especially squamous cell carcinoma patients.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/40/2/923}, eprint = {https://ar.iiarjournals.org/content/40/2/923.full.pdf}, journal = {Anticancer Research} }